PreveCeutical Medical Inc.
PREV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.78% | 16.91% | -30.82% | -39.99% | -17.05% |
| Depreciation & Amortization | 2.78% | -27.45% | -20.65% | -12.05% | -2.70% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.79% | 13.83% | -27.67% | -36.05% | -14.55% |
| Operating Income | 18.79% | -13.83% | 27.67% | 36.05% | 14.55% |
| Income Before Tax | 9.03% | -158.04% | -13.45% | 14.13% | 19.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.03% | -158.04% | -13.45% | 14.13% | 19.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.03% | -158.04% | -13.45% | 14.13% | 19.14% |
| EBIT | 18.79% | -13.83% | 27.67% | 36.05% | 14.55% |
| EBITDA | 19.01% | -14.58% | 27.71% | 36.27% | 14.67% |
| EPS Basic | 5.88% | -216.67% | -13.33% | 16.67% | 22.73% |
| Normalized Basic EPS | 9.09% | -200.00% | -22.22% | 9.09% | 8.33% |
| EPS Diluted | 5.88% | -216.67% | -13.33% | 16.67% | 22.73% |
| Normalized Diluted EPS | 9.09% | -200.00% | -22.22% | 9.09% | 8.33% |
| Average Basic Shares Outstanding | 0.19% | 0.47% | 0.96% | 1.46% | 2.60% |
| Average Diluted Shares Outstanding | 0.19% | 0.47% | 0.96% | 1.46% | 2.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |